On May 14, 2026, Inventurus Knowledge Solutions Limited (IKS Health) informed the stock exchanges regarding the successful completion of its acquisition of Arai Solutions Private Limited. The company has acquired 10,000 equity shares, representing 100% of the target’s share capital, for a total cash consideration of INR 11 Crores. This follows the initial board approval and disclosure made on May 13, 2026, marking a swift transition of the entity into a wholly-owned subsidiary of IKS Health.

The acquisition is a strategic move to accelerate IKS Health’s development of a full “agentic AI” technology stack. Arai Solutions, an innovation-driven AI provider incorporated in April 2024, specializes in biomedical knowledge graphs and explainable AI frameworks. By integrating Arai’s clinical reasoning and medical ontologies, IKS Health aims to make its AI operational models more economical and reliable, particularly for high-stakes applications like autonomous medical coding, denial prevention, and precision medicine. This “glass box” AI approach ensures that clinical predictions remain transparent and traceable for regulators.

Inventurus Knowledge Solutions Limited (IKS Health) is a technology-enabled healthcare solutions provider primarily serving physician enterprises and healthcare organizations in the US, Canada, and Australia. In May 2026, the company also announced a strategic partnership with Holyoke Medical Center in Massachusetts to reduce administrative burdens through its care enablement platform. Additionally, the company recently signed a definitive agreement to acquire TruBridge Inc. for approximately USD 575 Million to expand its footprint in the US rural healthcare market. These updates align with IKS Health’s “True North” target of achieving INR 3,000 Crores in EBITDA by FY30.

For the quarter ended March 31, 2026, the company reported a robust financial performance with consolidated net profit jumping 33.3% year-on-year to INR 206 Crores. Revenue from operations for the same period hit INR 858 Crores, an 18.4% increase compared to the corresponding quarter of the previous year. This growth was driven by strong operational leverage and improved realization from its healthcare solutions portfolio. A notable aspect of the company’s investor profile is its backing by the Jhunjhunwala family, who are prominent long-term promoters of the firm. Recent 2025 reports also highlighted that Motilal Oswal and Jefferies have maintained bullish outlooks on the stock due to its consistent profit growth and high return on equity.